Cimzia Keeps Raking In The Cash As UCB Waits For New Products Impact
TNF Blocker Peaks Early
Executive Summary
The Belgian group’s older products helped push 2022 revenues to the top of their guidance range as the peak sales forecast for the new epilepsy drug Fintepla is set at €800m.
You may also be interested in...
UCB Aims High In Hidradenitis Suppurativa After Bimzelx Success
Topline results from two Phase III studies show the Belgian group's dual IL-17A and IL-17F inhibitor met its primary and secondary endpoints ahead of a filing for hidradenitis suppurativa next year. How well it compares with Humira and Cosentyx in this indication remains to be seen, however.
UCB Makes Another Push To Get Bimzelx Over Finishing Line In US
The Belgian group was stunned by an FDA rejection in May for its dual IL-17A and IL-17F inhibitor and although the refiling is complete, UCB may still have to wait six months to get Bimzelx into the all-important US psoriasis market.
UCB Rocked By US FDA Rejection Of Blockbuster-In-Waiting Bimzelx
The Belgian group’s US launch of Bimzelx could be delayed by up to a year after the FDA hit UCB with a complete response letter which states that "certain pre-approval inspection observations must be resolved” before the drug can get the green light for psoriasis.